
Patients with multiple sclerosis (MS) who took the new generation anti-inflammatory medication natalizumab for two years had a lower risk of experiencing relapses and progression of their disability, according to a new study.
MS experts say the research is useful because it confirms results from earlier trials.
Natalizumab (NTZ), which is also known by its brand name Tysabri, is recommended for use in the NHS for patients with severe relapsing-remitting MS which is deteriorating quickly. It is administered by intravenous infusion once a month.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768